 Chemical Structure.png)
AVL-3288 (UCI-4083; UCI4083; CCMI; XY-4083; Anvylic-3288; AVL3288) is an orally bioavailable and selective allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR) with neuroprotective effects. AVL-3288 showed preclinical efficacy in rat paradigms of attention and memory, including models of cognitive dysfunction1-3. AVL-3288 evokes positive modulation of acetylcholine (ACh)-induced EC5 currents (EC50 = 0.7 μM). AVL-3288 exhibits cognitive-enhancing properties in rodent models; displays no cytotoxic effects in PC12 cells or rat primary cortical neurons.
Physicochemical Properties
| Molecular Formula | C19H15CL2N3O2 |
| Molecular Weight | 388.248 |
| Exact Mass | 387.054 |
| CAS # | 917837-54-8 |
| Related CAS # | 917837-54-8; |
| PubChem CID | 16005981 |
| Appearance | Light yellow to yellow solid powder |
| Density | 1.412±0.06 g/cm3(Predicted) |
| Boiling Point | 605.4±55.0 °C |
| LogP | 5.527 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 26 |
| Complexity | 501 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CC1=NOC(=C1)/C(=C/NC2=CC=C(C=C2)Cl)/C(=O)NC3=CC=C(C=C3)Cl |
| InChi Key | VMAKIACTLSBBIY-BOPFTXTBSA-N |
| InChi Code | InChI=1S/C19H15Cl2N3O2/c1-12-10-18(26-24-12)17(11-22-15-6-2-13(20)3-7-15)19(25)23-16-8-4-14(21)5-9-16/h2-11,22H,1H3,(H,23,25)/b17-11- |
| Chemical Name | (Z)-3-(4-chloroanilino)-N-(4-chlorophenyl)-2-(3-methyl-1,2-oxazol-5-yl)prop-2-enamide |
| Synonyms | Anvylic-3288 UCI-4083AVL-3288 UCI-4083UCI4083CCMIXY-4083 Anvylic-3288AVL3288XY-4083 XY 4083 XY4083 UCI4083 UCI 4083 CCMI |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | CCMI (Compound 6) is a strong and specific positive allosteric modulator of α7 nAChR. It significantly increases the positive modulation of α7 nAChR agonist-induced currents without binding to or activating α7 nAChR through the orthosite [1]. |
| References |
[1]. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A. 2007 May 8;104(19):8059-64. Epub 2007 Apr 30. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~257.57 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5757 mL | 12.8783 mL | 25.7566 mL | |
| 5 mM | 0.5151 mL | 2.5757 mL | 5.1513 mL | |
| 10 mM | 0.2576 mL | 1.2878 mL | 2.5757 mL |